Loading company…
Shanghai biotech developing single-agent and combination anti-tumor drugs for patients with drug-resistant tumors.
Established in 2017 and based in Shanghai, China, Ringene Biopharma researches and develops innovative anti-tumor drugs. It works on single-agent or combination drugs for drug-resistant tumor patients, using a structural biology-guided design platform focused on the RTK-MAPK pathway. The company closed an angel round in August 2018. In September 2020, SDIC Venture Capital and Shenzhen Capital Group co-led its Series A funding, which it plans to use for preclinical development and translational medicine platforms.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in